Literature DB >> 22212601

Soluble receptor for advanced glycation end-product levels are related to albuminuria and arterial stiffness in essential hypertension.

K Dimitriadis1, C Tsioufis, A Kasiakogias, A Miliou, M Poulakis, K Kintis, I Bafakis, E Benardis, D Tousoulis, C Stefanadis.   

Abstract

BACKGROUND AND AIMS: Emerging evidence suggests that the soluble receptor for advanced glycation end-products (sRAGE) is implicated in the development of vascular disease. We investigated the interrelationships of sRAGE with albumin to creatinine ratio (ACR) and arterial stiffness in essential hypertension. METHODS AND
RESULTS: In 309 untreated non-diabetic hypertensives, ACR values were determined as the mean of three non-consecutive morning spot urine samples and aortic stiffness was evaluated on the basis of carotid to femoral pulse wave velocity (c-f PWV). In all subjects, venous blood sampling was performed for the estimation of sRAGE levels. Patients with low (n = 155) compared to those with high sRAGE values (n = 154) had greater 24-h systolic BP (140 ± 8 vs. 134 ± 7 mmHg, p < 0.0001), exhibited higher ACR (36.3 ± 51.6 vs. 17.2 ± 1.2 mg g(-1), p < 0.0001) and c-f PWV (8.3 ± 1.5 vs. 7.8 ± 1.1 m s(-1), p = 0.003), independently of confounding factors. Multiple regression analyses revealed that age, male sex, 24-h systolic BP and sRAGE were the 'independent correlates' of ACR (R(2) = 0.493, p < 0.0001), while age, 24-h systolic BP and sRAGE were the 'independent correlates' of c-f PWV (R(2) = 0.428, p < 0.0001).
CONCLUSION: In hypertensives, decreased sRAGE levels are accompanied by pronounced albuminuria and arterial stiffening. The association of sRAGE with ACR and c-f PWV suggests involvement of sRAGE in the progression of hypertensive vascular damage.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22212601     DOI: 10.1016/j.numecd.2011.10.003

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  6 in total

Review 1.  Do Advanced Glycation End Products and Its Receptor Play a Role in Pathophysiology of Hypertension?

Authors:  Kailash Prasad; Manish Mishra
Journal:  Int J Angiol       Date:  2017-02-03

2.  Soluble receptor for advanced glycation end products and increased aortic stiffness in the general population.

Authors:  Otto Mayer; Jitka Seidlerová; Jan Filipovský; Petra Vágovičová; Peter Wohlfahrt; Renata Cífková; Jindra Windrichová; Ondřej Topolčan
Journal:  Hypertens Res       Date:  2015-12-03       Impact factor: 3.872

3.  Soluble receptor for advanced glycation end-products independently influences individual age-dependent increase of arterial stiffness.

Authors:  Július Gelžinský; Otto Mayer; Jitka Seidlerová; Markéta Mateřánková; Štěpán Mareš; Veronika Kordíková; Ladislav Trefil; Renata Cífková; Jan Filipovský
Journal:  Hypertens Res       Date:  2019-10-21       Impact factor: 3.872

4.  Serum biomarkers, skin autofluorescence and other methods. Which parameter better illustrates the relationship between advanced glycation end products and arterial stiffness in the general population?

Authors:  Július Gelžinský; Otto Mayer; Jitka Seidlerová; Markéta Mateřánková; Štěpán Mareš; Veronika Kordíkova; Ladislav Trefil; Renata Cífková; Jan Filipovský
Journal:  Hypertens Res       Date:  2021-01-12       Impact factor: 3.872

5.  Low Soluble Receptor for Advanced Glycation End Products Precedes and Predicts Cardiometabolic Events in Women With Rheumatoid Arthritis.

Authors:  Mitra Nadali; Lovisa Lyngfelt; Malin C Erlandsson; Sofia Töyrä Silfverswärd; Karin M E Andersson; Maria I Bokarewa; Rille Pullerits
Journal:  Front Med (Lausanne)       Date:  2021-01-28

6.  sRAGE and risk of diabetes, cardiovascular disease, and death.

Authors:  Elizabeth Selvin; Marc K Halushka; Andreea M Rawlings; Ron C Hoogeveen; Christie M Ballantyne; Josef Coresh; Brad C Astor
Journal:  Diabetes       Date:  2013-02-08       Impact factor: 9.461

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.